This issue of Hematology/Oncology Clinics, guest edited by Drs. Ronald Hoffman, Ross Levine, John Mascarenhas, and Raajit Rampal, is dedicated to Myeloproliferative Neoplasms. This issue is one of six selected each year by the series consulting editors, Drs. George P. Canellos and Edward J. Benz. Topics in this issue include-but are not limited to- Overview of pathophysiology and potential drug targets, The role of the megakaryocyte, Epigenetics, Genetics, Novel technologies for understanding MPN biology, Important pathology considerations, Current Clinical investigations, Quality of life, Application of stem cell therapy, Immunotherapy approaches, Clinical unmet needs in ET/PV, Accelerated and blast phase MPNs, Epidemiology, Thrombotic and hemorrhagic complications, Murine modeling, The microenvironment in MPNs, MDS/MPN overlap syndrome, and Advancing effective clinical trial designs.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
Authors
John Mascarenhas Associate Professor of MedicineTisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY. Associate Professor of Medicine
Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai
New York, NY Ronald Hoffman Albert A. and Vera G. List Professor of Medicine, Tisch Cancer Institute, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. Ross Levine Memorial SloHuman Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA.an-Kettering Cancer Center. Human Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA. Raajit Rampal Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
